key: cord-0709775-2e8y9k5q authors: Khoshnood, Saeed; Arshadi, Maniya; Akrami, Sousan; Koupaei, Maryam; Ghahramanpour, Hossein; Shariati, Aref; Sadeghifard, Nourkhoda; Heidary, Mohsen title: An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines date: 2022-04-14 journal: J Clin Lab Anal DOI: 10.1002/jcla.24418 sha: 0c22e856fc43eaa22c3277cb99ee3df545f15a7b doc_id: 709775 cord_uid: 2e8y9k5q After about 2 years since severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), first infections were detected in Wuhan city of China in December 2019, which was followed by a worldwide pandemic with a record of 5.41 million deaths. Due to urgent need for the development of a safe and effective vaccine for coronavirus disease 2019 (COVID‐19), attempts for producing efficient vaccines are inexhaustibly continuing. According to a report by the World Health Organization (WHO) on COVID‐19 vaccine tracker and landscape, there are 149 vaccine candidates all over the world. Inactivated SARS‐CoV‐2 vaccines as a conventional vaccine platform consist of whole virus particles grown in cell culture and inactivated by chemicals. Because of benefits such as antigenic similarity to real virion inducing humoral and cellular immune responses and ease for transport and storage, these vaccines, including the vaccines produced by Bharat Biotech, Sinopharm, and Sinovac, are in use at large scales. In this study, we have a review on inactivated SARS‐CoV‐2 vaccines that are passing their phase 3 and 4 clinical trials, population which was included in the trials, vaccine producers, the efficiency, adverse effects, and components of vaccines, and other vaccine features. The world community has been battling a global epidemic for about 2 years. Coronavirus disease 2019 is caused by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). 1 Recent studies have reported cellular and humoral immune responses to COVID-19 in infected patients ( Figure 1A,B) . Due to the high-rate transmission of the Middle East respiratory coronavirus compared with SARS-CoV-2, the need for an immediate vaccine design for this virus is exceedingly felt. 2 Vaccines are used for the prevention and treatment of COVID-19. 3 DNA-based vaccines, RNA-based vaccines, recombinant subunit vaccines, adenovirus-based vectors, and inactivated viruses are various types of SARS-CoV-2 vaccines that have lately been developed. 4 In many countries of the world, vaccination has been or is being carried out on a large scale, especially among frontline workers. 5 According to a document prepared by the US Food and Drug Administration, COVID-19 vaccines must have key attributes, for example, clinical data, toxicity, and description of immune responses in the animal model, to be licensed. 6 Inactivated vaccines are produced through the growth of SARS-CoV-2 in the cell culture and subsequent inactivation of the virus. 7 There are several methods of inactivation, such as the use of formaldehyde, glutaraldehyde, ultraviolet, and gamma rays. 8 Therefore, a biosafety level 3 is required to produce inactivated vaccines. Different countries, including China, Kazakhstan, and India, have developed this type of vaccine. Inactivated vaccines are given intramuscularly. Immune responses are induced against the spike proteins, matrix, envelope, and nucleoprotein. 7 The level of antibodies decreases over time, indicating the need for a long-term study of the protective effect of inactivated vaccines. 9 Ease of use is one of the benefits of using inactivated vaccines. So far, SARS-CoV-2 adjuvants have been evaluated in humans to be used for the improvement of immunogenicity. 10 Another merit of inactivated vaccines is their high speed of development, which makes them a viable option for developing COVID-19 vaccines. 2 Moreover, inactivated vaccines can be stored at 2-8°C, making them suitable for countries with limited cold storage capacity. 11 However, there are disadvantages such as the need for high levels of contagious virus. 10 Virus antigens and epitopes may be destroyed during the inactivation process, leading to a weakened immune response. 8 Inactivated vaccines have hitherto been developed for two viral diseases, influenza virus and poliovirus. 12 As of June 21, 2021, 1049 doses of SARS-CoV-2 inactivated vaccine had been vaccinated in China. 13 Due to genetic changes in the SARS-CoV-2 genome, the emergence of new strains of the virus is often observed. The effect of vaccines on these new strains has not yet been determined. 14 With this in mind, this study was undertaken to evaluate the efficacy and immunogenicity of various inactivated vaccines produced against SARS-CoV-2. such as COVI-VAC deliver a robust immune response and are associated with the long-lasting cellular immunity. 15 The results of a preclinical study performed to assess the immunogenicity and safety of COVI-VAC in Syrian golden hamsters (Mesocricetus auratus) have demonstrated that this vaccine is safe and effective in small animal models at a single dose. Also, lower tissue viral loads and milder lung pathology were observed in Syrian golden hamsters vaccinated with COVI-VAC compared with those inoculated with wild-type viruses. In addition, the vaccine appeared to be resistant to reversal and could grow to a large extent. 16 In another study, the efficiency of this vaccine was evaluated against challenge with the Beta (B.1.351) variant in the same hamsters. Twenty-seven days' postvaccination by COVI-VAC, animals were challenged intranasally with wild-type SARS-CoV-2 Beta variant. According to this report, COVI-VAC stimulates serum and mucosal antibody immune responses. 19 NCT05233826 is an ongoing phase 1 clinical trial study evaluating the safety and immunization of COVI-VAC as a booster dose in 30 healthy adults previously vaccinated with authorized mRNA or adenovirus vectors vaccine against COVID-19. There is still no available report on its results. 20 ISRCTN15779782 is an ongoing large, international, randomized controlled phase 3 clinical trial designed to provide adequate evidence of the safety and efficacy of this vaccine and is supported by the World Health Organization (WHO). The volunteers, healthy adults (aged ≥ 16 years) were randomly allocated either to placebo or vaccine group. 21 No results from this phase have been published so far. CoronaVac, also known as the Sinovac COVID-19 vaccine, is a two-dose β-propiolactone (BPL)-inactivated aluminum hydroxideadjuvanted SARS-CoV-2 vaccine produced by Sinovac Research and Development Co., Ltd. CoronaVac is one of the eight emergency use listing vaccines approved by WHO in 54 countries all over the world. 22 A double-blind, placebo-controlled, phase 1/2 clinical trial (NCT04383574) of this vaccine was performed in 422 healthy adults aged 60 years and older in China. In phase 1, participants (n = 72) received a 3μg or 6μg vaccine or placebo. In phase 2, participants (n = 350) were given either CoronaVac at 1.5, 3, or 6 µg per dose or placebo. In the safety populations from both phases, any adverse reaction within 28 days after injection occurred in 20% of participants in the 1.5μg group, 20% in the 3μg group, 22% in the 6μg group, and 21% in the placebo group. All adverse reactions were mild or moderate in severity, and injection site pain was the most frequently reported event. In phase 1, seroconversion after the second dose was observed in 100% of participants in the 3μg group and 95.7% in the 6μg group. In phase 2, seroconversion was identified in 90.7% of participants in the 1.5μg group, 98% in the 3μg group, and 99% in the 6 μg group. There were no detectable antibody responses in the placebo group. 23 To assess the immune persistence of a two-dose schedule of CoronaVac, and the immunogenicity and safety of its third dose in healthy adults aged 18 years and older, a double-blind, randomized, placebo-controlled phase 2 clinical trial was conducted. There were two vaccination schedule cohorts: days 0 and 14 (cohort 1) and days 0 and 28 (cohort 2) vaccination cohorts. Half of the subjects in each cohort were selected to receive an additional dose 28 days after the second dose, and the other half of the subjects were chosen to receive the third dose 6 months after the second dose. The results of these trials showed that a two-dose schedule of CoronaVac could generate favorable immune memory. Although neutralizing antibody titers decreased to near or below the lower limit of seropositivity 6 months after the second dose, the third dose given 8 months after the second dose was highly effective at recalling a SARS-CoV-2specific immune response. 24 It consists of BPL inactivated the whole virus with high spike protein density, combined with two adjuvants, alum and Dynavax's CpG Preclinical studies have suggested that combination of adjuvantinduced high titers of neutralizing antibodies is associated with a shift in the cellular immune response toward Th1. 32 The hCoV-19/Turkey/ERAGEM-001/2020 strain was employed to test the safety of ERUCOV-VAC. In BALB/c mice, the vaccine was found to be highly immunogenic and induced a significant immune response. In K18-hACE2 mice, the ERUCOV-VAC vaccine displayed 100% protection against a lethal SARS-CoV-2 challenge. In the ferret models, viral clearance rates were similar to the safety assessment of the vaccine in upper respiratory tracts. The most prevalent minor adverse effect was discomfort at the place of the injection. 44 ERUCOV-VAC is presently in phase 3 clinical trial (NCT04942405). Its name was shifted to TURKOVAC in this phase. protection against the SARS-CoV-2 variant of concern, B.1.617.2 (Delta). There was no report of anaphylaxis or deaths in relation to the vaccine. BBV152 was well-tolerated with an incidence of AVs over a median of 146 days, which was less than that detected in other COVID-19 vaccines. 51 The safety and immunogenicity of BBV152, adjuvanted with aluminum hydroxide gel (Algel) or a novel TLR7/8 agonist chemisorbed Algel, were examined in another study. In this regard, a strain of SAS-CoV-2 and a Vero cell platform were selected to induce a highly purified inacti- (Table 1) . 69 In another recent survey, Jingwen Ai et al. In addition, whole microbial vaccines provide faster immunity than vaccines based on nucleic acid, protein, and viral vector. The remarkable point is that nucleic acid-based vaccines are slower to develop than other types of vaccines, but they are safe and effective. 71 One of the most important issues in relation to vaccines is the emergence of new strains of SARS-CoV-2. Natural selection is responsible for choosing mutations to maintain the survival, proliferation, and fitness of organisms. 75 Therefore, the immunogenicity of vaccines against new strains requires constant evaluation. Research has emphasized that the Omicron variant declines the neutralization ability of vaccines by evading neutralizing antibodies, which reduces immune responses. Decreased immune responses were found to be even less than in Mu and Beta strains. 76 Studies have pointed out that after injecting two doses of inactivated vaccine, a booster is needed. Booster vaccines can be a variety of mRNAs, protein subunits, and inactivated vaccines. 70, 77, 78 Immunoglobulin immune responses to Omicron variant occur only after booster injection. 79 In one study, the protective effect of BBIBP-CorV against new variants, B.1.1.7 in the UK (Alpha) and B.1.351 in South Africa (Beta), and Wuhan-1 reference strain (wild-type) was assessed. The results showed that BBIBP-CorV was more effective against B.1.1.7 than B.1.351. 80 The efficacy of BBV152/COVAXIN against the Alpha strain and COVI-VAC vaccine against Beta strain has also been highlighted. 17, 81 The results of an investigation on the protective effect of the CoronaVac against seven variants of The efficiency of available vaccines against new strains is a subject that needs further investigation. The authors declare that they have no conflict of interest. SK, MA, SA, MK, HG, NS, and MH contributed to comprehensive research and wrote the paper. AS participated in editing the manuscript. Notably, all authors have read and approved the manuscript. The authors confirm that the data supporting the findings of this study are available within the article. Mohsen Heidary https://orcid.org/0000-0002-9839-5017 1. Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52(4):583-589. No Adjuvant COVI-VAC stimulates serum and mucosal antibody immune responses based on phase 1 trial Well-tolerated, with no significant adverse events reported across the 48 patients enrolled in phase 1 16, 19 Aluminum hydroxide 50.7% against symptomatic COVID−19 and 100% against hospitalization based on phase3 trial in Brazil, 65.9% based on study in Chile and 83% based on phase 3 in Turkey Mild/moderate, and most of the common adverse events were pain at the injection site, headache, fatigue, and myalgia [26] [27] [28] Alum and CpG 1018 Good humoral and cellular immune responses, based on phase 1/2 trial. Superiority against ChAdOx1-S in terms of geometric mean titer for neutralization antibodies based on phase 3. Safe and well-tolerated tenderness, pain, headache and fatigue [34] [35] [36] Aluminum Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2 A systematic review of SARS-CoV-2 vaccine candidates Development of an inactivated vaccine candidate for SARS-CoV-2 Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile SARS-CoV-2 vaccine development: current status SARS-CoV-2 vaccines in development Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine Current advances in the development of SARS-CoV-2 vaccines Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study SARS-CoV-2 viral variantstackling a moving target Innovators target vaccines for variants and shortages in global south Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy COVI-VAC™, a live attenuated COVID-19 vaccine, provides single dose protection against heterologous challenge with SARS-CoV-2 Beta (B. 1.351) in the Syrian Golden Hamster Model Safety and immunogenicity of COVI-VAC, a live attenuated vaccine against COVID-19 Codagenix presents positive phase 1 data for COVI-VAC Intranasal COVID-19 Vaccine at IDWeek 2021 Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19 Solidarity trial of candidate vaccines against COVID-19 Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac (Guidance). W; 2021 Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (Inactivated) vaccine manufactured by Sinovac-PROFISCOV: a structured summary of a study protocol for a randomised controlled trial Evidence assessment: Sinovac/CoronaVac COVID-19 vaccine Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines. medRxiv The architecture of inactivated SARS-CoV-2 with postfusion spikes revealed by Cryo-EM and Cryo-ET Development of CpGadjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19 Dose finding study to evaluate the safety taioai, adjuvanted SARS-CoV-2 virus vaccine candidate against covid-19 in healthy subjects Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1/2 clinical trial Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial Valneva reports positive phase 3 results for inactivated, adjuvanted COVID-19 vaccine candidate VLA2001 Clinical characteristics, diagnosis, treatment, and mortality rate of TB/COVID-19 coinfectetd patients. A systematic review Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001 Valneva Receives Emergency Use Authorization from Bahrain for its Inactivated COVID-19 Vaccine VLA2001 Development of an Inactivated Vaccine against SARS CoV-2. Vaccines COVID-19 pneumonia in patients with HIV: a case series Safety and potency of COVIran Barekat inactivated vaccine candidate for SARS-CoV-2: A preclinical study Evaluation of post-vaccination signs and symptoms among iranian health professionals vaccinated by different types of COVID-19 vaccine Covaxin: An overview of its immunogenicity and safety trials in India Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised Evaluation of safety and immunogenicity of an adjuvanted, TH-1 skewed, whole virion inactivated SARS-CoV-2 vaccine-BBV152 COVID19 vaccine: COVAXIN ® -India's first indigenous effective weapon to fight against coronavirus (A review) Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city The Hindu. October 23 Uhwtcbc-i-tfae Development of the inactivated QazCovid-in vaccine: protective efficacy of the vaccine in Syrian Hamsters Safety and immunogenicity of a QazCovid-in ® inactivated whole-virion vaccine against COVID-19 in healthy adults: a single-centre, randomised, singleblind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in ® , in healthy adults: a multicentre, randomised, single-blind SARS-CoV-2 inactivated vaccine (Vero cells) shows good safety in repeated administration toxicity test of Sprague Dawley rats The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial Efficacy of the vaccines, their safety, and immune responses against SARS-CoV-2 infections Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial Safety and immunogenicity of a heterologous boost with a recombinant vaccine Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7 Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the United Arab Emirates Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments Opportunities and challenges in the delivery of mRNA-based vaccines Status report on COVID-19 vaccines development Effectiveness of an inactivated SARS-CoV-2 vaccine SARS-CoV-2 new variants: characteristic features and impact on the efficacy of different vaccines Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections or vaccinees Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant BNT162b2 vaccine boosts neutralizing antibodies to ancestral SARS-CoV-2 & Omicron variant in adults received 2-dose inactivated vaccine Landscape of the RBD-specific IgG, IgM, and IgA responses triggered by the inactivated virus vaccine against the Omicron variant Susceptibility of circulating SARS-CoV-2 variants to neutralization Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B. 1.1. 7 variant of SARS-CoV-2 Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac CoviVac vaccination induces production of neutralizing antibodies against Delta and Omicron variants of SARS-CoV-2. medRxiv Towards a Brucella vaccine for humans Co-culture-inducible bacteriocin production in lactic acid bacteria An overview on inactivated and live-attenuated SARS-CoV-2 vaccines